eligibility_summary
Eligible: unresectable/metastatic colorectal cancer (post-therapy), advanced/metastatic PDAC (post-therapy), or advanced/unresectable biliary tract cancer (with or without prior therapy). Previously treated participants must have recovered from prior side effects. Exclude: severe eye disease, prior systemic anticancer therapy within 4 weeks (if previously treated), history/current pneumonitis or ILD requiring steroids.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Phase 1/2 trial in advanced/unresectable colorectal, pancreatic, and biliary tract cancers. Interventions: (1) Sacituzumab tirumotecan (MK‑2870/SKB264) monotherapy—an antibody–drug conjugate (ADC) targeting TROP2 that delivers a topoisomerase I inhibitor to tumor cells, (2) MK‑2870 + 5‑fluorouracil (antimetabolite inhibiting thymidylate synthase) + leucovorin (folinic acid that potentiates 5‑FU), (3) MK‑2870 + cisplatin (DNA cross‑linking platinum) + pembrolizumab (anti‑PD‑1 monoclonal antibody checkpoint inhibitor). Targets/pathways: TROP2‑expressing epithelial tumor cells, topo I–mediated DNA replication, thymidylate synthase, DNA cross‑link damage/repair, PD‑1/PD‑L1 axis activating cytotoxic T cells.